The FDA has cleared for marketing three computer-assisted detection technologies developed by iCAD: iDM, which works with Fischer Imaging's SenoScan full-field digital mammography system; iAD, a full-featured stand-alone unit, and iQ, a low-cost
The FDA has cleared for marketing three computer-assisted detection technologies developed by iCAD: iDM, which works with Fischer Imaging's SenoScan full-field digital mammography system; iAD, a full-featured stand-alone unit, and iQ, a low-cost stand-alone unit. Following the FDA approvals, iCAD and Fischer announced an expanded development and distribution agreement that includes the new iAD product, which reads digitized mammography films. iCAD, located in Nashua, NH, plans to market the device to women's health centers and breast clinics that perform fewer than 20 mammography procedures a day.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.